Increase inNRASmutant allele percentage during metastatic melanoma progression

SIRT1 regulates Mxd1 during malignant melanoma progression

In a murine melanoma model, malignant transformation promoted by a sustained stress condition was causally related to increased levels of reactive oxygen species resulting in DNA damage and massive epigenetic alterations. Since the chromatin modifier Sirtuin-1 (SIRT1) is a protein attracted to double-stranded DNA break (DSB) sites and can recruit other components of the epigenetic machinery, we...

Fulminant hepatic failure due to metastatic choroidal melanoma

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma

Despite markedly improved treatment options for metastatic melanoma, resistance to targeted therapies such as BRAF inhibitors (BRAFi) or BRAFi plus MEK inhibitors (MEKi) remains a major problem. Our aim was to characterize progression on BRAFi therapy and outcome of subsequent treatment. One hundred and eighty patients with BRAF-mutant metastatic melanoma who had progressed on treatment with si...

Acute gout during treatment with paclitaxel for metastatic melanoma.

MOTOHISA YAMAMOTO, HIROKI TAKAHASHI, KOHHEI HASEBE, CHISAKO SUZUKI, YASUYOSHI NAISHIRO, TOSHIAKI HAYASHI, HIROYUKI YAMAMOTO, TADAO ISHIDA, YASUHISA SHINOMURA First Department of Internal Medicine, Sapporo Medical University School of Medicine, Department of General Internal Medicine, Teine Keijinkai Hospital and Biomedical Research Center, Department of Biomedical Engineering, Sapporo Medical U...

Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma.

© 2016 The Authors. doi: 10.2340/00015555-2212 Journal Compilation © 2016 Acta Dermato-Venereologica. ISSN 0001-5555 Programmed cell death (PD)-1 is an immune checkpoint receptor expressed on antigen-stimulated T cells. Several types of anti-PD-1 antibodies have demonstrated a remarkable benefit for metastatic melanoma, with a low incidence of severe adverse events. A fully human antiPD-1 antib...